Sarcosine as an add-on treatment to antipsychotic medication for people with schizophrenia: a systematic review and meta-analysis of randomized controlled trials

References

• Morin AM, Hattori H, Wasterlain CG, et al. [3H]MK-801 binding sites in neonate rat brain. Brain Res. 1989;487:376–379.
   PubMed Web of Science ®Google Scholar
• Balu DT. The NMDA receptor and schizophrenia: from pathophysiology to treatment. Adv Pharmacol San Diego Calif. 2016;76:351–382.
   PubMedGoogle Scholar
• Curtis D. A possible role for sarcosine in the management of schizophrenia. Br J Psychiatry J Ment Sci. 2019;215:697–698.
   PubMed Web of Science ®Google Scholar
• Dalmau J, Lancaster E, Martinez-Hernandez E, et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011;10:63–74.
   PubMed Web of Science ®Google Scholar
• Dalmau J, Tüzün E, Wu H, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol. 2007;61:25–36.
   PubMed Web of Science ®Google Scholar
• Meixensberger S, Tebartz van Elst L, Schweizer T, et al. Anti-N-Methyl-D-Aspartate-Receptor encephalitis: a 10-year follow-up. Front Psychiatry. 2020;11:245.
   PubMed Web of Science ®Google Scholar
• Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994;51:199–214.
   PubMed Web of Science ®Google Scholar
• Malhotra AK, Pinals DA, Weingartner H, et al. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 1996;14:301–307.
   PubMed Web of Science ®Google Scholar
• Malhotra AK, Pinals DA, Adler CM, et al. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 1997;17:141–150.
   PubMed Web of Science ®Google Scholar
• Saini SM, Mancuso SG, Mostaid MS, et al. Meta-analysis supports GWAS-implicated link between GRM3 and schizophrenia risk. Transl Psychiatry. 2017;7:e1196.
   PubMed Web of Science ®Google Scholar
• Fromer M, Pocklington AJ, Kavanagh DH, et al. De novo mutations in schizophrenia implicate synaptic networks. Nature. 2014;506:179–184.
   PubMed Web of Science ®Google Scholar
• Kirov G, Pocklington AJ, Holmans P, et al. De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia. Mol Psychiatry. 2012;17:142–153.
   PubMed Web of Science ®Google Scholar
• Purcell SM, Moran JL, Fromer M, et al. A polygenic burden of rare disruptive mutations in schizophrenia. Nature. 2014;506:185–190.
   PubMed Web of Science ®Google Scholar
• Snyder MA, Gao W-J. NMDA receptor hypofunction for schizophrenia revisited: perspectives from epigenetic mechanisms. Schizophr Res. 2020;217:60–70.
   PubMed Web of Science ®Google Scholar
• Uno Y, Coyle JT. Glutamate hypothesis in schizophrenia. Psychiatry Clin Neurosci. 2019;73:204–215.
   PubMed Web of Science ®Google Scholar
• Wenneberg C, Glenthøj BY, Hjorthøj C, et al. Cerebral glutamate and GABA levels in high-risk of psychosis states: a focused review and meta-analysis of 1H-MRS studies. Schizophr Res. 2020;215:38–48.
   PubMed Web of Science ®Google Scholar
• Olagunju AT, Clark SR, Baune BT. Clozapine and psychosocial function in schizophrenia: a systematic review and meta-analysis. CNS Drugs. 2018;32:1011–1023.
   PubMed Web of Science ®Google Scholar
• Elkis H, Buckley PF. Treatment-resistant schizophrenia. Psychiatr Clin North Am. 2016;39:239–265.
   PubMed Web of Science ®Google Scholar
• NICE NI for H and CE. Psychosis and schizophrenia in adults: prevention and management. [Internet]. NICE; 2014 [cited 2020 Apr 6]. Available from: https://www.nice.org.uk/guidance/cg178/chapter/1-Recommendations#subsequent-acute-episodes-of-psychosis-or-schizophrenia-and-referral-in-crisis-2.
   Google Scholar
• Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45:789–796.
   PubMed Web of Science ®Google Scholar
• Sommer IE, Begemann MJH, Temmerman A, et al. Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. Schizophr Bull. 2012;38:1003–1011.
   PubMed Web of Science ®Google Scholar
• Heresco-Levy U, Javitt DC, Ebstein R, et al. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol Psychiatry. 2005;57:577–585.
   PubMed Web of Science ®Google Scholar
• Heresco-Levy U, Javitt DC, Ermilov M, et al. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry. 1999;56:29–36.
   PubMed Web of Science ®Google Scholar
• Heresco-Levy U, Ermilov M, Lichtenberg P, et al. High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biol Psychiatry. 2004;55:165–171.
   PubMed Web of Science ®Google Scholar
• Tsai GE, Yang P, Chang Y-C, et al. D-alanine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry. 2006;59:230–234.
   PubMed Web of Science ®Google Scholar
• Goff DC, Tsai G, Levitt J, et al. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry. 1999;56:21–27.
   PubMed Web of Science ®Google Scholar
• Heresco-Levy U, Ermilov M, Shimoni J, et al. Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. Am J Psychiatry. 2002;159:480–482.
   PubMed Web of Science ®Google Scholar
• Singh SP, Singh V. Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia. CNS Drugs. 2011;25:859–885.
   PubMed Web of Science ®Google Scholar
• Kantrowitz JT, Epstein ML, Lee M, et al. Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: correlation with symptoms. Schizophr Res. 2018;191:70–79.
   PubMed Web of Science ®Google Scholar
• Cho S-E, Na K-S, Cho S-J, et al. Low d-serine levels in schizophrenia: a systematic review and meta-analysis. Neurosci Lett. 2016;634:42–51.
   PubMed Web of Science ®Google Scholar
• Fukuyama K, Kato R, Murata M, et al. Clozapine normalizes a glutamatergic transmission abnormality induced by an impaired NMDA receptor in the Thalamocortical Pathway via the activation of a group III metabotropic glutamate receptor. Biomolecules. 2019;9:234.
   PubMed Web of Science ®Google Scholar
• Herdon HJ, Godfrey FM, Brown AM, et al. Pharmacological assessment of the role of the glycine transporter GlyT-1 in mediating high-affinity glycine uptake by rat cerebral cortex and cerebellum synaptosomes. Neuropharmacology. 2001;41:88–96.
   PubMed Web of Science ®Google Scholar
• Javitt DC, Balla A, Sershen H, et al. Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors. Biol Psychiatry. 1999;45:668–679.
   PubMed Web of Science ®Google Scholar
• Tsai GE, Lin P-Y. Strategies to enhance N-Methyl-D-Aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. Curr Pharm Des. 2010;16:522–537.
   PubMed Web of Science ®Google Scholar
• Iwata Y, Nakajima S, Suzuki T, et al. Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials. Mol Psychiatry. 2015;20:1151–1160.
   PubMed Web of Science ®Google Scholar
• Marchi M, Galli G, Magarini FM, et al. Sarcosine as an add-on treatment to antipsychotic medication for people with schizophrenia and other psychotic disorders: a systematic review and meta-analysis of randomized controlled trials. [Internet]. PROSPERO CRD42019141455. 2019 [cited 2020 Apr 6]. Available from: https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=141455.
   Google Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261–276.
   PubMed Web of Science ®Google Scholar
• Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, N.J: Routledge; 1988.
   Google Scholar
• Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ [Internet]. 2011 [cited 2020 Mar 25];343. Available from: https://www.bmj.com/content/343/bmj.d5928.
   Google Scholar
• Higgins JPT, Thomas J Cochrane handbook for systematic reviews of interventions [Internet]. 2019 [cited 2020 Apr 6]. Available from: /handbook/current.
   Google Scholar
• Schünemann H, Brożek J, Guyatt G, et al. GRADE handbook for grading quality of evidence and strength of recommendations. [Internet]. 2013 [cited 2020 Apr 6]. Available from: https://gdt.gradepro.org/app/handbook/handbook.html.
   Google Scholar
• Lane H-Y, Liu Y-C, Huang C-L, et al. Sarcosine (N-Methylglycine) treatment for acute schizophrenia: a randomized, double-blind study. Biol Psychiatry. 2008;63:9–12.
   PubMed Web of Science ®Google Scholar
• Strzelecki D, Kałużyńska O, Szyburska J, et al. No changes of cardiometabolic and body composition parameters after 6-month add-on treatment with sarcosine in patients with schizophrenia. Psychiatry Res. 2015;230:200–204.
   PubMed Web of Science ®Google Scholar
• Strzelecki D, Kałużyńska O, Szyburska J, et al. MMP-9 serum levels in schizophrenic patients during treatment augmentation with sarcosine (results of the PULSAR study). Int J Mol Sci. [Internet]. 2016 [cited 2019 Jul 4];17. Available from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4964451/
   PubMed Web of Science ®Google Scholar
• Strzelecki D, Kałużyńska O, Wysokiński A. BDNF serum levels in schizophrenic patients during treatment augmentation with sarcosine (results of the PULSAR study). Psychiatry Res. 2016;242:54–60.
   PubMed Web of Science ®Google Scholar
• Strzelecki D, Podgórski M, Kałużyńska O, et al. Adding sarcosine to antipsychotic treatment in patients with stable schizophrenia changes the concentrations of neuronal and glial metabolites in the Left Dorsolateral Prefrontal Cortex. Int J Mol Sci. 2015;16:24475–24489.
   PubMed Web of Science ®Google Scholar
• Strzelecki D, Podgórski M, Kałużyńska O, et al. Supplementation of antipsychotic treatment with the amino acid sarcosine influences proton magnetic mesonance spectroscopy parameters in Left Frontal White Matter in patients with schizophrenia. Nutrients. 2015;7:8767–8782.
   PubMed Web of Science ®Google Scholar
• Strzelecki D, Urban-Kowalczyk M, Wysokiński A. Serum levels of TNF-alpha in patients with chronic schizophrenia during treatment augmentation with sarcosine (results of the PULSAR study). Psychiatry Res. 2018;268:447–453.
   PubMed Web of Science ®Google Scholar
• Strzelecki D, Urban‐Kowalczyk M, Wysokiński A. Serum levels of interleukin 6 in schizophrenic patients during treatment augmentation with sarcosine (results of the PULSAR study). Hum Psychopharmacol Clin Exp. 2018;33:e2652.
   PubMed Web of Science ®Google Scholar
• Lane H-Y, Chang Y-C, Liu Y-C, et al. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch Gen Psychiatry. 2005;62:1196–1204.
   PubMed Web of Science ®Google Scholar
• Lane H-Y, Huang C-L, Wu P-L, et al. Glycine Transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biol Psychiatry. 2006;60:645–649.
   PubMed Web of Science ®Google Scholar
• Lane H-Y, Lin C-H, Huang Y-J, et al. A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and d-serine add-on treatment for schizophrenia. Int J Neuropsychopharmacol. 2010;13:451–460.
   PubMed Web of Science ®Google Scholar
• Lin C-Y, Liang S-Y, Chang Y-C, et al. Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: a randomised, double-blind, placebo-controlled trial. World J Biol Psychiatry. 2017;18:357–368.
   PubMed Web of Science ®Google Scholar
• Strzelecki D, Podgórski M, Kałużyńska O, et al. Supplementation of antipsychotic treatment with sarcosine – glyT1 inhibitor – causes changes of glutamatergic 1NMR spectroscopy parameters in the left hippocampus in patients with stable schizophrenia. Neurosci Lett. 2015;606:7–12.
   PubMed Web of Science ®Google Scholar
• Tsai G, Lane H-Y, Yang P, et al. Glycine transporter I inhibitor, N-Methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry. 2004;55:452–456.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. (DSM-IV). 4th ed. Washington, DC: American Psychiatric Press; 1994.
   Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th Edition, Text Revision (DSM IV-TR). 4th ed. Washington, DC: American Psychiatric Press; 2000.
   Google Scholar
• Leucht S, Kane JM, Kissling W, et al. What does the PANSS mean? Schizophr Res. 2005;79:231–238.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Li T, Deeks JJ Chapter 6: choosing effect measures and computing estimates of effect. Cochrane Handb Syst Rev Interv [Internet]. 6.1. Cochrane; 2020. [cited 2020 Nov 30]. Available from: /handbook/current/chapter-06.
   Google Scholar
• Reid MA, Salibi N, White DM, et al. 7T proton magnetic resonance spectroscopy of the anterior cingulate cortex in first-episode schizophrenia. Schizophr Bull. 2019;45:180–189.
   PubMed Web of Science ®Google Scholar
• Amiaz R, Kent I, Rubinstein K, et al. Safety, tolerability and pharmacokinetics of open label sarcosine added on to anti-psychotic treatment in schizophrenia - preliminary study. Isr J Psychiatry Relat Sci. 2015;52:12–15.
   PubMed Web of Science ®Google Scholar
• Rosenheck R, Evans D, Herz L, et al. How long to wait for a response to clozapine: a comparison of time course of response to clozapine and conventional antipsychotic medication in refractory schizophrenia. Schizophr Bull. 1999;25:709–719.
   PubMed Web of Science ®Google Scholar
• Ankerst DP, Liss M, Zapata D, et al. A case control study of sarcosine as an early prostate cancer detection biomarker. BMC Urol. [Internet]. 2015 [cited 2020 Mar 24];15. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4591628/
   PubMed Web of Science ®Google Scholar
• Jentzmik F, Stephan C, Miller K, et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur Urol. 2010;58:12–18. discussion 20-21.
   PubMed Web of Science ®Google Scholar
• Heger Z, Merlos Rodrigo MA, Michalek P, et al. Sarcosine up-regulates expression of genes involved in cell cycle progression of metastatic models of prostate cancer. PloS One. 2016;11:e0165830.
   PubMed Web of Science ®Google Scholar
• Sreekumar A, Poisson LM, Rajendiran TM, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009;457:910–914.
   PubMed Web of Science ®Google Scholar
• Chang C-H, Lin C-H, Liu C-Y, et al. Efficacy and cognitive effect of sarcosine (N-methylglycine) in patients with schizophrenia: a systematic review and meta-analysis of double-blind randomised controlled trials. J Psychopharmacol. 2020;34:495–505.
   Web of Science ®Google Scholar
• Bugarski-Kirola D, Wang A, Abi-Saab D, et al. A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia - results from the CandleLyte study. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2014;24:1024–1036.
   PubMed Web of Science ®Google Scholar
• Bugarski-Kirola D, Blaettler T, Arango C, et al. Bitopertin in negative symptoms of schizophrenia-results from the phase III FlashLyte and DayLyte Studies. Biol Psychiatry. 2017;82:8–16.
   PubMed Web of Science ®Google Scholar
• Kantrowitz JT, Nolan KA, Epstein ML, et al. Neurophysiological effects of bitopertin in schizophrenia. J Clin Psychopharmacol. 2017;37:447–451.
   PubMed Web of Science ®Google Scholar
• Javitt DC, Duncan L, Balla A, et al. Inhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action. Mol Psychiatry. 2005;10:275–287.
   PubMed Web of Science ®Google Scholar
• Rotella F, Cassioli E, Calderani E, et al. Long-term metabolic and cardiovascular effects of antipsychotic drugs. A meta-analysis of randomized controlled trials. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2020;32:56–65.
   PubMed Web of Science ®Google Scholar
• Azorin J-M SN. Antipsychotic polypharmacy in schizophrenia: evolving evidence and rationale. Expert Opin Drug Metab Toxicol. 2020;16:1175–1186.
   PubMed Web of Science ®Google Scholar
• Bleuler E. Dementia Praecox oder Gruppe der Schizophrenien. Leipzig and Vienna: Granz Deuticke; 1911.
   Google Scholar
• Abbink K, Harris D. In-group favouritism and out-group discrimination in naturally occurring groups. Plos One. 2019;14:e0221616.
   PubMed Web of Science ®Google Scholar